Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
The UNIVERSITY OF ULSTER currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 2 distinct examiners and 2 distinct art units. Such a distribution suggests that the university's current patenting efforts involve different technical or procedural aspects within the biotechnology field. The presence of 2 distinct art units indicates that the university must navigate the specific examination standards and procedural nuances of each unit separately.
BROWN, MINDY G is the busiest examiner for this portfolio, with 1 pending office action currently under review. Because there are 2 distinct examiners for the 2 pending office actions, the workload is shared between different individuals. This requires the university to adapt to different examination styles simultaneously. The 1 pending office action assigned to Brown represents a specific point of contact for the university's prosecution strategy in this sector.
For practitioners, the 2 pending office actions require a strategy that accounts for the individual tendencies of 2 distinct examiners. Maintaining consistency in claim language across 2 distinct art units is essential for a cohesive intellectual property approach. Counsel should monitor the 1 pending office action assigned to Brown while also addressing the other pending matter in the Biotechnology & Pharmaceuticals sector. This dual focus ensures that all technical requirements are met across the 2 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BROWN, MINDY G | 1 | 55.9% | +44.4% |
| HANEY, AMANDA MARIE | 1 | 36.4% | +44.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17999616 | A GENETIC TEST TO PREDICT ANTI-TNF DRUG RESPONSE | HANEY, AMANDA MARIE | 2d overdue |
| 18012505 | A METHOD OF PREDICTING RESPONSE TO TREATMENT WITH A DISEASE-MODIFYING ANTI-RHEUMATIC DRUG, AND/OR CLASSIFYING DISEASE ACTIVITY IN A SUBJECT WITH RHEUMATOID ARTHRITIS | BROWN, MINDY G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17999616 | A GENETIC TEST TO PREDICT ANTI-TNF DRUG RESPONSE | HANEY, AMANDA MARIE | 2d overdue |
| 18012505 | A METHOD OF PREDICTING RESPONSE TO TREATMENT WITH A DISEASE-MODIFYING ANTI-RHEUMATIC DRUG, AND/OR CLASSIFYING DISEASE ACTIVITY IN A SUBJECT WITH RHEUMATOID ARTHRITIS | BROWN, MINDY G | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18012505 | A METHOD OF PREDICTING RESPONSE TO TREATMENT WITH A DISEASE-MODIFYING ANTI-RHEUMATIC DRUG, AND/OR CLASSIFYING DISEASE ACTIVITY IN A SUBJECT WITH RHEUMATOID ARTHRITIS | BROWN, MINDY G | 1683 | §101§112 | Non-Final OA | — | Pending | Dec 22, 2022 |
| 17999616 | A GENETIC TEST TO PREDICT ANTI-TNF DRUG RESPONSE | HANEY, AMANDA MARIE | 1682 | §101§103 | Final Rejection | 2d overdue | Pending | Nov 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial